Coya Therapeutics (COYA) Expected to Announce Earnings on Tuesday

Coya Therapeutics (NASDAQ:COYA) is anticipated to issue its Q1 2026 results before the market opens on Tuesday, May 12th. Analysts expect the company to announce earnings of ($0.39) per share and revenue of $0.15 million for the quarter. Individuals may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Friday, May 15, 2026 at 9:30 AM ET.

Coya Therapeutics (NASDAQ:COYA) last released its quarterly earnings results on Monday, March 16th. The company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.26). The firm had revenue of $3.96 million during the quarter, compared to analyst estimates of $1.93 million. Coya Therapeutics had a negative net margin of 267.13% and a negative return on equity of 62.76%. On average, analysts expect Coya Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Coya Therapeutics Stock Down 1.4%

NASDAQ:COYA traded down $0.06 on Tuesday, reaching $4.20. The stock had a trading volume of 118,426 shares, compared to its average volume of 185,052. The company has a market capitalization of $98.53 million, a P/E ratio of -3.31 and a beta of 0.55. The stock has a fifty day moving average price of $4.45 and a 200-day moving average price of $5.17. Coya Therapeutics has a 1-year low of $3.71 and a 1-year high of $7.75.

Institutional Investors Weigh In On Coya Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in COYA. Alyeska Investment Group L.P. acquired a new stake in shares of Coya Therapeutics during the fourth quarter worth $4,640,000. AWM Investment Company Inc. acquired a new stake in Coya Therapeutics in the 4th quarter valued at approximately $4,205,000. Private Management Group Inc. acquired a new stake in Coya Therapeutics in the 4th quarter valued at approximately $1,626,000. Marshall Wace LLP raised its position in Coya Therapeutics by 438.8% in the 4th quarter. Marshall Wace LLP now owns 225,358 shares of the company’s stock valued at $1,307,000 after buying an additional 183,533 shares during the last quarter. Finally, Dauntless Investment Group LLC raised its position in Coya Therapeutics by 199.5% in the 3rd quarter. Dauntless Investment Group LLC now owns 153,021 shares of the company’s stock valued at $872,000 after buying an additional 101,932 shares during the last quarter. 39.75% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts have weighed in on the company. D. Boral Capital reissued a “buy” rating and issued a $15.00 target price on shares of Coya Therapeutics in a research note on Friday, April 10th. Wall Street Zen raised Coya Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, April 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Coya Therapeutics in a report on Monday, April 20th. Chardan Capital reiterated a “buy” rating and issued a $14.00 target price on shares of Coya Therapeutics in a report on Monday, March 16th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $18.00 price objective on shares of Coya Therapeutics in a research note on Monday, March 23rd. Five investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $16.00.

About Coya Therapeutics

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.